|
First clinical trials
Immutep S.A. announced today that its lead product ImmuFact® IMP321 has moved into Phase I/II clinical trials. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response in therapeutic vaccines.Please, clic on ADOBE PDF logo to open the complete communique. Published 04/2005 by admin@immutep.com © 2002 Immutep, S.A.
|
Press Release
04/2012 - Immutep and Lonza Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact® IMP321
Immutep and Lonza announced today an agreement for cell line ...
02/2012 - Interview Frederic Triebel with PharmaTelevision 
Get the Flash ...
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases 
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer. 
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial 
Immutep S.A. announced today that the final results from its Phase ...
|
|||||||
